Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer

PURPOSE: Exemestane, a steroidal aromatase inhibitor, reduced invasive breast cancer incidence by 65% among 4,560 postmenopausal women randomly assigned to exemestane (25 mg per day) compared with placebo in the National Cancer Institute of Canada (NCIC) Clinical Trials Group MAP.3 (Mammary Preventi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Maunsell, Elizabeth, Goss, Paul E., Chlebowski, Rowan T., Ingle, James N., Alés-Martínez, José E., Sarto, Gloria E., Fabian, Carol J., Pujol, Pascal, Ruiz, Amparao, Cooke, Andrew L., Hendrix, Susan, Thayer, Debra W., Rowland, Kendrith M., Dubé, Pierre, Spadafora, Silvana, Pruthi, Sandhya, Lickley, Lavina, Ellard, Susan L., Cheung, Angela M., Wactawski-Wende, Jean, Gelmon, Karen A., Johnston, Dianne, Hiltz, Andrea, Brundage, Michael, Pater, Joseph L., Tu, Dongsheng, Richardson, Harriet
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2014
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879707/
https://ncbi.nlm.nih.gov/pubmed/24711552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.2483
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados